Author Interviews, Cancer Research / 20.04.2015
Antifungal Drug May Be Repurposed As An Anti-Cancer Agent
MedicalResearch.com Interview with:
Pan Pantziarka, PhD
Member of the ReDO project and the Anticancer Fund
Research from the Repurposing Drugs in Oncology (ReDO) project
MedicalResearch: What is the background for this study?
Dr. Pantziarka: This study is one of a number initiated by the Repurposing Drugs in Oncology (ReDO) project. ReDO is an international collaboration between the Belgian foundation the Anticancer Fund and the US not-for-profit GlobalCures. ReDO includes researchers based in the UK, Belgium and the US. The project aims to identify the most promising non-cancer drugs which have evidence that they may be effective additions to oncological treatments. Itraconazole, the subject of this study, is a well-characterised and commonly used anti-fungal agent that is available internationally and at relatively low cost.
MedicalResearch: What are the main findings?
Dr. Pantziarka: We have summarised a broad range of in vitro, in vivo and clinical evidence of anti-cancer activity in itraconazole. In particular there is strong evidence that itraconazole has activity against the Hedgehog signalling pathway, which is active in a variety of different cancer indications. Our study also includes details of a number of positive clinical trials which have reported, and includes details of some still in progress. The level of evidence is particularly striking in basal cell carcinoma, prostate and lung cancer.
(more…)